A Randomized, Double-blind, Placebo, Parallel-Controlled, Multicenter Phase 2a Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SIM0278 in Subjects With Active Lupus Nephritis
Latest Information Update: 11 Feb 2026
At a glance
- Drugs ALM-223 (Primary)
- Indications Lupus nephritis
- Focus Therapeutic Use
- Sponsors Simcere Pharmaceutical Group
Most Recent Events
- 11 Feb 2026 New trial record